Modelled DT Structure
Method: homology modeling
Template PDB: 5EQG_A
Identity: 65.253%
Minimized Score: -1345.831 kcal/mol
Detail: Structure Info
| General Information of DT | |||||
|---|---|---|---|---|---|
| DT ID | DTD0262 | ||||
| Gene Name | SLC2A4 | ||||
| Protein Name | Glucose transporter type 4, insulin-responsive | ||||
| Gene ID | |||||
| UniProt ID | |||||
| TCDB ID | |||||
| 3D Structure |
Modelled DT Structure Method: homology modeling Template PDB: 5EQG_A Identity: 65.253% Minimized Score: -1345.831 kcal/mol Detail: Structure Info |
||||
| Synonyms | GLUT-4; GLUT4; SLC2A4; Solute carrier family 2, facilitated glucose transporter member 4 | ||||
| DT Family | Major Facilitator Superfamily (MFS) | ||||
| Sugar Porter (SP) Family | |||||
| Tissue Specificity | Skeletal and cardiac muscles; brown and whitefat. | ||||
| Function | This insulin-regulated transporter facilitates glucose transport. | ||||
| Endogenous Substrate(s) | Glucose | ||||
| Variability Data of This Drug Transporter (DT) | |||||
|
Regulatory Variability Data of This DT (VARIDT 3.0) |
|||||
|
(α) Microbiota Influence of This DT |
|||||
|
(β) Post-translational Modification of This DT |
|||||
|
(γ) Transcriptional Regulation of This DT |
|||||
|
(δ) Epigenetic Regulation of This DT |
|||||
|
(ε) Exogenous Modulation of This DT |
|||||
|
Structural Variability Data of This DT (VARIDT 2.0) |
|||||
|
(β) Inter-species Structural Differences |
|||||
|
(γ) Outward/inward-facing Conformation |
|||||
|
(δ) Xenobiotics-regulated Structural Variability |
|||||
|
General Variability Data of This DT (VARIDT 1.0) |
|||||
|
(α) Genetic Polymorphisms of This DT |
|||||
|
(β) Disease-specific Protein Abundances of This DT |
|||||
|
(γ) Species- and Tissue-specific DT Abundances |
|||||
| Molecular Transporting Profile of This DT | |||||
|
Full List of Drug(s) Transported by This DT |
|||||
|
Clinical Trial Drug |
Click to Show/Hide the Full List of Drug: 1 Drugs in Total | ||||
| Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
|
2-Deoxyglucose
|
Phase 1/2 | Drug Info | Cancer | 2A00-2F9Z | [1] |
| References | |||||
| 1 | Need for GLUT4 activation to reach maximum effect of insulin-mediated glucose uptake in brown adipocytes isolated from GLUT4myc-expressing mice. Diabetes. 2002 Sep;51(9):2719-26. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.